Europe Dengue Treatment Market, By Strains (DENV-1, DENV-2, DENV-3, DENV-4 and Others), Transmission (Mosquito-To-Human Transmission, Mother-To-Child Transmission and Others), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania and Rest of Europe) Industry Trends and Forecast to 2028
Market Analysis and Insights: Europe Dengue Treatment Market
Dengue treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 22.5% in the forecast period of 2021 to 2028 and is expected to reach USD 73.75 million by 2028 from USD 14.94 million in 2020. Strategic initiatives by market players and advent of mass vaccination programmes for dengue treatment are likely to be the major drivers which propelled the demand of the market in the forecast period.
Dengue fever is a mosquito- borne viral infection. Female mosquitoes transmit the dengue virus primarily from the species Aedes aegypti and to a lesser degree, from Ae. albopictus. Chikungunya, yellow fever and Zika viruses are the disease caused by these vector mosquitoes. Dengue is prevalent in the tropics, with local risk variability caused by precipitation, temperature, relative humidity and unplanned rapid urbanizationThe diagnosis of dengue fever is difficult, since its signs and symptoms are similar to those of chikungunya, Zika virus, malaria and typhoid fever. Dengue is a mosquito-borne tropical disease caused by the dengue virus (DENV-1, DENV-2, DENV-3, DENV-4). Symptoms typically begin three to fourteen days after infection.
The treatment of dengue is totally based on treating the symptoms such as for high fever, acetaminophen is generally prescribed to control fever and relives pain. Aspirin and ibuprofen should be avoided for treating dengue fever. In case of severe dengue supportive care is given with the proper monitoring of the symptoms such as belly pain, internal bleeding and shock.
Acetaminophen, chloramphenicol, ciprofloxacin, ceftriaxone, ranitidine, pantoprazole are prescribed in dengue fever, with supportive care and available vaccines in the market. The increasing prevalence of dengue, advent of vaccination programs, growth of medical insurance in emerging countries and increasing R&D funding expected to drive the dengue treatment market growth. Moreover, strategic initiative by market player and technological development to detect dengue bolsters the dengue treatment market growth.
The dengue treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Dengue Treatment Market Scope and Market Size
Dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of strain, the dengue treatment market is segmented into DENV-1, DENV-2, DENV-3, DENV-4, others. In 2021, DENV-2 segment is dominating the market as this strain is high in prevalence globally which result in higher infection cases of dengue fever. Although dengue can be csued by other strains too but the most dominant high clinical complication is seen in DENV-2.
- On the basis of transmission, the dengue treatment market is segmented into mosquito-to-human transmission and mother-to-child transmission. In 2021, mosquito-to-human is dominating in the market as the mosquitoes are the primary vector for the transmission of dengue for the different strains of the virus. When a mosquito bites an infected person it gets infected too and gets the virus in blood, and when a he again bite some other person the virus get transmitted to that person. This is the reason that mosquito-to-human transmission is dominating the market.
- On the basis of type, the dengue treatment market is segmented into medication, supportive care, vaccination and others. In 2021, medication segment are dominating in the Europe Dengue Treatment Market as variety of drugs used for treating dengue are being used for the management of dengue fever from the very long time.
- On the basis of severity, the dengue treatment market is segmented into uncomplicated and severe. In 2021, uncomplicated segment is dominating in the Europe Dengue Treatment Market as the conversion rate of uncomplicated dengue to severe dengue is less than 5% which is the most important reason that the uncomplicated segment is dominating the Europe Dengue Treatment Market.
- On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. Oral is sub-segmented into tablets, pills and others. Parenteral is sub-segmented into intravenous, subcutaneous and others. In 2021, oral segment is dominating in the Europe Dengue Treatment Market as most of the drug that are taken to treat the symptoms of dengue are taken oral for pain management and fever management.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and OTC. In 2021, prescription is dominating in the Europe Dengue Treatment Market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2021, home healthcare is dominating the Europe Dengue Treatment Market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the Europe Dengue Treatment Market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Dengue Treatment Market Country Level Analysis
The dengue treatment market is analysed and market size information is provided by country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel.
The countries covered in the dengue treatment market report are Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania and Rest of Europe.
Europe is expected to grow with the CAGR in the forecasted period due to growing R&D activities in pharma and biotech sector. Germany is expected to dominate in the Europe market. Germany is one of the leading countries in automation with increasing number of upgradation of the software driven compound management.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Initiatives by Market Players are creating new Opportunities in the Dengue Treatment Market
Dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Dengue Treatment Market Share Analysis
Dengue treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to dengue treatment market.
The major companies providing dengue treatment are Takeda Pharmaceutical Company Limited, Sanofi, EMERGEX VACCINES, ABIVAX, GlaxoSmithKline plc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Baxter, among others.
The strategic initiatives by market players with capital investment for dengue research are bridging the gap between dengue and its treatment.
- In 2016, Sun Pharmaceutical Industries Ltd. and International Centre for Genetic Engineering and Biotechnology (ICGEB) announced collaboration for developing novel dengue vaccine for India and global market.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the dengue treatment market which also provides the benefit for organisation to improve their offering for treatment products.
SKU-